Branded
Compounded
Branded vs. Compounded
Branded GLP-1s have FDA oversight and consistent manufacturing. Compounded versions are significantly cheaper but carry risks around dosing accuracy, sterility, and the use of unapproved salt forms.
Key Metrics
Branded
Compounded
FDA-approved
Not FDA-approved (503B pharmacy)
GLP-1 Agonist (brand-name formulation)
GLP-1 Agonist (compounded formulation)
~12–21% (varies by specific drug)
Similar efficacy expected (limited data)
Branded
Key Advantages
- Full FDA oversight and consistent manufacturing quality
- Exact dosing with pre-filled pens
- Insurance coverage pathways available
Compounded
Key Advantages
- 60–80% cheaper than branded retail pricing
- Accessible through telehealth without prior authorization
- Available when branded supply is limited
Trusted Telehealth Providers
Safety first. Access genuine medications through verified medical platforms with board-certified clinical supervision.
Henry Meds
Specializing in transparent, monthly subscription models for compounded options.
Hims
Streamlined digital-first experience with competitive all-in pricing.
Ro Weight Loss
White-glove concierge insurance support for brand-name GLP-1 therapy.
Overview
Compounded semaglutide costs $297–$499/month vs $1,350+ for branded Wegovy. But the FDA has raised quality and safety concerns about compounded versions.
Key Differences
| Factor | Branded GLP-1s | Compounded GLP-1s |
|---|---|---|
| FDA Status | FDA-approved | Not FDA-approved |
| Monthly Cost | $850–$1,350 retail | $149–$499 via telehealth |
| Manufacturing | Pharmaceutical-grade facility | 503A or 503B compounding pharmacy |
| Dosing | Pre-filled pens, exact dosing | Vials requiring manual drawing |
| Quality Testing | Extensive FDA oversight | State pharmacy board oversight |
| Insurance | Coverage pathways available | No insurance coverage |
| Supply | Generally stable (post-shortage) | Regulatory uncertainty in 2026 |
| Available Forms | Injection + oral tablet | Injection only |
The Regulatory Landscape (2026)
In February 2026, the FDA officially ended the semaglutide shortage declaration. This has major implications for compounded GLP-1s:
- 503B compounders can now only compound semaglutide for patients with documented medical needs (allergies, unique dosing)
- 503A compounders (traditional pharmacies) can still compound with valid individual prescriptions
- Several telehealth providers have already shifted to offering brand-name medications through manufacturer programs
Cost Comparison
| Access Path | Monthly Cost | Notes |
|---|---|---|
| Branded Wegovy (retail) | ~$1,349/mo | Full price, no programs |
| Branded Wegovy (NovoCare) | $349/mo | Self-pay program |
| Branded Wegovy Pill | $149–$299/mo | Oral, cheapest branded option |
| Branded Zepbound (LillyDirect) | $299–$449/mo | Self-pay program |
| Compounded semaglutide | $149–$299/mo | Regulatory uncertainty |
| Compounded tirzepatide | $199–$399/mo | Regulatory uncertainty |
Key insight: With the Wegovy Pill at $149/mo and Zepbound at $299/mo through manufacturer programs, the price gap between branded and compounded has narrowed significantly. The value proposition of compounded is weaker than it was in 2024–2025.
Quality Considerations
- Branded: Manufactured in FDA-inspected facilities with strict quality controls. Pre-filled pens ensure exact dosing.
- Compounded: Quality varies by pharmacy. The FDA has issued warnings about compounded semaglutide products containing semaglutide sodium salt (not the same molecular form as Ozempic/Wegovy). Vials require manual drawing, introducing dosing variability.
How It Compares
- Oral vs Injectable GLP-1 — the new oral options vs injections
- Semaglutide vs Tirzepatide — comparing the two main drug classes
- Complete GLP-1 Cost Guide — every pricing pathway
Frequently Asked Questions
Are compounded GLP-1s safe?
Compounded medications from licensed 503B pharmacies undergo batch-level quality testing, but they are not FDA-approved products — a meaningful distinction. The FDA has flagged specific concerns about compounded semaglutide products: dosing accuracy issues from manual vial drawing (vs. pre-filled pens), sterility failures in some facilities, and most significantly, the use of semaglutide sodium salt instead of semaglutide base. The sodium salt form is a chemically distinct compound that is not the same molecule as the FDA-approved drug in Ozempic and Wegovy. The FDA has issued warning letters to multiple compounders over these issues. That said, reputable 503B outsourcing facilities with current USP 797/800 accreditation and third-party Certificate of Analysis testing do maintain meaningful quality standards. If you’re using compounded GLP-1s, verify your pharmacy holds 503B facility status, not just 503A (traditional pharmacy). Ask for the batch-level Certificate of Analysis before accepting a shipment. The safest approach is transitioning to FDA-approved branded products, which are now available at competitive prices.
Can I still get compounded semaglutide in 2026?
The FDA ended the semaglutide shortage declaration in February 2026, which significantly restricts what compounders can legally produce and distribute at scale. Following the shortage end, 503B outsourcing facilities can only compound semaglutide for patients with documented medical needs — such as verified allergies to Wegovy or Ozempic excipients, medically necessary alternative dosing forms, or documented insurance access failures where branded products are unsuitable. Routine production of compounded semaglutide for general weight loss patients is no longer permitted under 503B regulations. However, 503A traditional compounding pharmacies can still fill patient-specific prescriptions in smaller volumes with a valid prescription from your provider. In practice, many telehealth platforms that previously offered compounded semaglutide at $149–299/month have already transitioned patients to branded NovoCare or LillyDirect programs. Availability is reduced and inconsistent as of April 2026. If you’re currently on compounded semaglutide, ask your provider about switching to the Wegovy Pill ($149/month through NovoCare) or Foundayo ($149/month) — both are FDA-approved oral alternatives at similar or lower price points than what compounded versions historically cost.
Should I switch from compounded to branded?
For most patients currently on compounded semaglutide, the case for switching to a branded option has strengthened significantly in 2026. The price gap has narrowed dramatically: Wegovy Pill starts at $149/month through NovoCare, injectable Wegovy is $349/month, and Zepbound is $299/month through LillyDirect — all within range of what compounded alternatives cost during the shortage period. Meanwhile, the FDA’s regulatory restrictions have reduced compounded availability and increased uncertainty about continuity of supply. Quality risks — including the semaglutide sodium salt issue and dosing variability — remain real with compounded products. Switching to a branded option provides FDA-assured quality, exact dosing via pre-filled pens, and supply stability. If you’re on compounded for cost reasons, run a comparison with the manufacturer self-pay programs before your next fill. The financial rationale for compounded is considerably weaker in April 2026 than it was in 2024.
Keep Reading
- How to Stop Semaglutide Without Gaining — transitioning safely
- GLP-1 Shortage Guide — current supply status
- Provider Reviews — compare telehealth platforms